Advera

Directions Website

Advera Peptide Therapy Education for Healthcare Professionals
Accredited CME • Evidence • Clinical Practice
Learn More ↓

10/21/2026

There's now a registered controlled human musculoskeletal trial of BPC-157, and the design is genuinely good.

Researchers are recruiting 120 adults aged 18 to 45 with an MRI-confirmed grade II hamstring strain, which is a partial muscle tear. Participants receive either BPC-157 or placebo for 14 days, and everyone follows the same standardised rehab program. Neither the patients nor the researchers know who received which until the study is over.

The endpoints are the part worth paying attention to. They repeat the MRI at day 14 to measure change in the actual injury volume, and they track how long it takes each person to resume sport and activity without restrictions.

That pairing is what makes it useful. The study isn't only asking what the muscle looks like on imaging. It's asking whether that healing translates into recovery and function. Those are different questions, and plenty of interventions change a scan without changing what a patient can do.

The trial is registered as NCT07437547 and listed as recruiting, so there are no results yet.

One point on how to read this. A ClinicalTrials.gov registration is a sponsor's statement that a study is planned. It is not evidence the study is running, that results exist, or that anything has been verified independently. If this completes and publishes, it would be the first controlled human data on BPC-157 and muscle healing. Until then the human evidence remains three small uncontrolled studies alongside a large preclinical literature.

Educational content, not individual medical advice.

Why would you deliberately activate glucagon in a metabolic drug?Glucagon raises blood sugar. That's the first thing any...
10/20/2026

Why would you deliberately activate glucagon in a metabolic drug?

Glucagon raises blood sugar. That's the first thing anyone learns about it.
Retatrutide hits three receptors: GLP-1, GIP and glucagon. Tirzepatide hits the first two.

The reason the third one is there: glucagon also drives hepatic fat breakdown and increases energy expenditure. Those are the effects you want. The glycemic effect is the cost.

So the GLP-1 and GIP activity does two jobs. It delivers its own benefits, and it offsets the glucose rise that glucagon would otherwise produce on its own.

The liver data is where this shows up. At 12 mg over 48 weeks, liver fat fell by an average of 86%, and 93% of patients with available MRI results had under 5% liver fat.

Three signals, balanced against each other. That's the design.
Swipe for the breakdown.

Explore our CME Program for clinicians looking to learn about peptide therapy: Link in bio!

One injection of CJC-1295 with DAC raised growth hormone for six days or more.CJC-1295 is a GHRH analog. It signals the ...
10/19/2026

One injection of CJC-1295 with DAC raised growth hormone for six days or more.

CJC-1295 is a GHRH analog. It signals the pituitary to release the body's own growth hormone. The DAC component binds albumin, which keeps it circulating far longer. Without DAC, the same molecule is much shorter acting.

In the 2006 study, one injection kept GH elevated for about six days and IGF-1 for nine to eleven.
GH was still released in pulses. The amount between those pulses was what climbed, and that changes what the receptor is exposed to over time.

Small studies in healthy adults, and the molecule never completed clinical development.
With DAC and without DAC are not interchangeable.

Full breakdown in the carousel.
Explore our CME Program for clinicians looking to learn about peptide therapy: Link in bio!

10/17/2026

For many clinicians, peptide therapy was never part of their formal education. These conversations are already happening in healthcare regardless.

That's an uncomfortable position to be in. A patient brings up a therapy nobody taught you, and you have to decide what to do with it while they're sitting there.

Learning peptide therapy can't stop at mechanisms and dosing protocols. You need to know how to take that science and apply it to the patient in front of you. That's the foundation of Advera's Patient-to-Plan Method: understand the peptide, evaluate the patient, build the plan, monitor and follow up.

It starts with understanding the peptide itself, which comes down to three questions you can ask about any molecule, including one you've never encountered.

What is it doing physiologically? What does the evidence show? What safety considerations come with that therapy?

Those three questions are portable. Work through them properly and you aren't waiting for someone to publish a protocol every time something new appears. You have a way of thinking it through yourself, which matters in a field that changes faster than any course can keep up with.

Educational content, not individual medical advice.

\ \ \ \

10/16/2026

A patient walks in asking about PT-141 for low libido. The clinical decision cannot start and stop with PT-141.

You still need to look at their medications, their hormones, their cardiovascular history, their overall health, and the other factors that may be contributing. Then you determine whether that peptide belongs in the plan, how it fits with everything else you're addressing, and what needs to be monitored once treatment begins.

Here's what makes that more than general thoroughness in this particular case. Bremelanotide, approved as Vyleesi, is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. It transiently raises blood pressure and lowers heart rate after each dose, peaking around two to four hours, and the label directs prescribers to assess cardiovascular risk before starting and periodically afterward. Cardiovascular history isn't a formality. It determines whether this is an option at all.

The approved indication is premenopausal women with acquired, generalised HSDD, where the low desire is not attributable to a coexisting medical or psychiatric condition, to relationship problems, or to the effects of a medication. Working through those possibilities isn't something added on top of the indication. It is the indication. A clinician who skips the workup has no way of knowing whether this patient is the patient the therapy was approved for.

It's also worth stating plainly that Vyleesi is not indicated for men, for postmenopausal women, or to enhance sexual performance.
That is patient-centred peptide therapy. The molecule the patient names is where the conversation starts, not where the decision gets made.

Educational content, not individual medical advice.

10/15/2026

Five CME credits is what you get on the certificate. It isn't the reason to do this. The value of the program goes deeper than that, and the goal is specific. You become the clinician who can sit across from a patient and understand the entire decision.

You understand the therapy. You understand the patient. You know what needs to be assessed, what could change the plan, what needs to be monitored, and how to move forward responsibly.

When all of that is in place, the clinical question changes shape. It stops being which peptide to use and becomes whether this one belongs in this patient's plan at all. Those are very different questions, and only one of them is actually clinical.

Peptide therapy should never be about fitting a patient into a protocol. It should be about understanding enough to determine what actually makes sense for that individual patient.

A credit tells someone you completed a program. It says nothing about whether you can do the work.

Educational content, not individual medical advice.

10/13/2026

Knowing what a peptide does tells you nothing about what to document, what to ask a compounding pharmacy, or where your scope ends.

That's the gap between understanding the medicine and actually being able to offer it, and it's why Peptide Therapy in Clinical Practice includes more than the clinical modules.

The Peptide Therapy Implementation Guide handles the practical side of bringing this into a practice. Workflow, compounding pharmacy due diligence, consent, documentation, compliance, and the legal responsibilities that come with patient care. Most programs stop before this part.

The Advera Clinical Companion is an approximately 80-page clinical reference covering 27 of the most high-interest peptides, with mechanisms, dosing ranges, assessments, contraindications, safety considerations, regulatory status, and clinical guidance organised in one place. Nobody carries 27 peptides in their head. You need something you can go back to on a Tuesday afternoon with a patient in front of you.

The private Advera clinician community is where healthcare professionals keep learning as the research, the regulation, and the clinical questions evolve. A course that sits still goes out of date in this field. A community doesn't.

The program is accredited through the International Institute of Continuing Medical Education and Advancing Knowledge in Healthcare, with 5 continuing medical education credits available to multiple healthcare disciplines.

Educational content, not individual medical advice.

10/12/2026

When someone tells me a peptide supports the mitochondria, I want to know what it actually does.

SS-31 targets cardiolipin, a phospholipid found in the inner mitochondrial membrane. That membrane folds inward, and those folds are called cristae. The cristae hold the protein complexes that cells use to produce ATP, which is the energy form cells actually use.
Cardiolipin keeps those folds and the proteins inside them organised. When cardiolipin becomes damaged, the structure loses stability, the proteins stop working together efficiently, and energy production can slow down.

SS-31 binds to cardiolipin, and laboratory and animal studies suggest this may help preserve the cristae and support ATP production. The mechanism is structural rather than fuel-based. It's protecting the machinery, not adding to the supply.

SS-31 is also called elamipretide, and it received FDA accelerated approval in September 2025 under the brand name Forzinity. The indication is Barth syndrome, a rare mitochondrial cardioskeletal disease, in adults and children weighing at least 30 kg, to improve muscle strength. Approval was based on a phase 2 trial and an improvement in knee extensor muscle strength, which is an intermediate endpoint.

So the same molecule has a real mechanism, real human data, and a genuine approval, all of which apply to a narrowly defined population and outcome. None of that makes it validated for general energy or mitochondrial support.
That gap between mechanism and demonstrated benefit is where most peptide conversations go wrong.
Educational content, not individual medical advice.

10/09/2026

One percent. That's how much of this pill reaches the bloodstream. It cuts LDL by 59 percent.

Most oral peptides have terrible bioavailability, which is why almost none of them reach the market. So when enlicitide posted LDL reductions near 60 percent, the first thing worth checking was how much drug actually gets absorbed.

About 1 percent.
Enlicitide blocks PCSK9, the protein that makes the liver break down LDL receptors. Those receptors clear LDL from the blood. Block PCSK9, more receptors stay, more LDL gets cleared.

The peptide is held in a tight macrocyclic ring for stability, and the tablet contains sodium caprate to help it cross the intestinal lining.
Even with all of that, roughly 1 percent makes it to circulation. Phase 3 still showed 56 to 59 percent placebo-adjusted LDL reduction. The FDA approved it in July 2026 as Lipfendra, the first oral PCSK9 inhibitor.

So it didn't solve poor oral peptide absorption. It was engineered to work despite it.
Bioavailability isn't pass or fail. It's one input into whether enough drug reaches the right place.

10/08/2026

A vendor tells you a peptide is 99 percent pure. Would that be enough to inject it?
It wouldn't be enough for me.

The number comes from a lab method that separates the sample into its components. A 99 percent result means the main peptide accounted for roughly 99 percent of the signal the test could detect, and that method may not detect everything present in the vial.

It also doesn't test sterility, and it doesn't test for endotoxins, which are harmful substances bacteria can leave behind even when no living bacteria remain. Sterilising something doesn't remove the toxins already left in it. Both of those require separate, specific testing.

That's why a purity figure alone isn't treated as adequate evidence of peptide quality for compounding. Purity, sterility and endotoxin content are three distinct questions, and a certificate that answers one of them is silent on the other two.

So 99 percent can read as reassuring while the risks that actually apply to injecting something haven't been assessed at all. I want evidence the finished vial is sterile and free of bacterial toxins before it goes anywhere near a patient.

Ask what was tested, by which method, and on which batch. A certificate from a different lot describes a different vial.

Address

Panama City, FL

Website

Alerts

Be the first to know and let us send you an email when Advera posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share